Beyond 68Ga-labeled somatostatin analogues: is it time to say goodbye to [68Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?

被引：0
|
作者：
Ninatti, Gaia [1 ,2 ]
Mapelli, Paola [2 ,3 ]
机构：
[1] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy
[2] IRCCS San Raffaele Sci Inst, Nucl Med Dept, Milan, Italy
[3] Univ Vita Salute San Raffaele, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / 08期
关键词：
D O I：
10.1007/s00259-023-06275-4
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：2246 / 2247
页数：2
相关论文
共 50 条
  • [31] Moving 68Ga-labeled DOTA PET Imaging Agents Towards Approval
    Graham, Michael
    Walker, Ronald
    Clarke, Bonnie
    Kiss, Christina
    Sunderland, John
    PANCREAS, 2014, 43 (03) : 496 - 496
  • [32] Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA
    Murat Fani Bozkurt
    Irene Virgolini
    Sona Balogova
    Mohsen Beheshti
    Domenico Rubello
    Clemens Decristoforo
    Valentina Ambrosini
    Andreas Kjaer
    Roberto Delgado-Bolton
    Jolanta Kunikowska
    Wim J. G. Oyen
    Arturo Chiti
    Francesco Giammarile
    Anders Sundin
    Stefano Fanti
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 2150 - 2151
  • [33] The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 18F-labeled Somatostatin Analog Development
    Waldmann, Christopher M.
    Stuparu, Andreea D.
    van Dam, R. Michael
    Slavik, Roger
    THERANOSTICS, 2019, 9 (05): : 1336 - 1347
  • [34] The potential role of 68Ga-labeled peptides in PET imaging of infection
    Sathekge, Mike
    NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (08) : 663 - 665
  • [35] [68Ga]-DOTATOC PET/CT in myocardial metastases of neuroendocrine neoplasms
    Yiraldine Herrera-Martínez
    José Luis Vercher-Conejero
    Juan José Martín-Marcuartu
    Alex Telué Vega
    Fernando Guerrero-Pérez
    Montserrat Cortés Romera
    Journal of Nuclear Cardiology, 2023, 30 : 1706 - 1708
  • [36] [68Ga]-DOTATOC PET/CT in myocardial metastases of neuroendocrine neoplasms
    Herrera-Martinez, Yiraldine
    Vercher-Conejero, Jose Luis
    Martin-Marcuartu, Juan Jose
    Telue Vega, Alex
    Guerrero-Perez, Fernando
    Cortes Romera, Montserrat
    JOURNAL OF NUCLEAR CARDIOLOGY, 2023, 30 (04) : 1706 - 1708
  • [37] Utility of 68Ga DOTATATE PET in Challenging Neuroendocrine Neoplasms' Scenarios
    O'Mahony, Furtado L.
    Kamieniarz, L.
    Leigh, C.
    Narayan, A.
    Bhatt, A.
    Miah, L.
    Cox, N.
    Hayes, A. R.
    Mandair, D.
    Caplin, M.
    Navalkissoor, S.
    Toumpanakis, C.
    NEUROENDOCRINOLOGY, 2019, 108 : 60 - 60
  • [38] Somatostatin Receptor PET in Neuroendocrine Tumors: 68Ga-DOTA-Tyr3-Octreotide vs. 68Ga-DOTA-Lanreotide
    Putzer, D.
    Kroiss, A.
    Waitz, D.
    Gabriel, M.
    Guggenberg, E.
    Uprimny, C.
    Decristoforo, C.
    Warwitz, B.
    Virgolini, I. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S273 - S273
  • [39] Role of Combined 68Ga DOTA-Peptides and 18F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
    Kaewput, Chalermrat
    Vinjamuri, Sobhan
    DIAGNOSTICS, 2022, 12 (02)
  • [40] 68Ga-labeled agonists with improved in vivo stability for imaging gastrin-releasing peptide receptor expression with positron emission tomography: comparison with [68Ga]Ga-AMBA and [68Ga]Ga-RM2
    Wang, Lei
    Kuo, Hsiou-Ting
    Zhang, Zhengxing
    Zhang, Chengcheng
    Merkens, Helen
    Colpo, Nadine
    Wilson, Ryan
    Zeisler, Jutta
    Benard, Francois
    Lin, Kuo-Shyan
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
12345